• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prognostic and monitoring potential of circulating tumor DNA in resectable pancreatic cancer.

作者信息

Labori Knut Jørgen

机构信息

Department of Hepato Pancreato Biliary Surgery, Oslo University Hospital, Oslo, Norway.

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

出版信息

Transl Gastroenterol Hepatol. 2025 Jun 26;10:37. doi: 10.21037/tgh-24-167. eCollection 2025.

DOI:10.21037/tgh-24-167
PMID:40755728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12314707/
Abstract
摘要

相似文献

1
Prognostic and monitoring potential of circulating tumor DNA in resectable pancreatic cancer.可切除胰腺癌中循环肿瘤DNA的预后及监测潜力
Transl Gastroenterol Hepatol. 2025 Jun 26;10:37. doi: 10.21037/tgh-24-167. eCollection 2025.
2
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.循环肿瘤 DNA 作为肌层浸润性膀胱癌围手术期治疗的预测和预后生物标志物：系统评价。
Eur Urol Oncol. 2024 Feb;7(1):44-52. doi: 10.1016/j.euo.2023.05.012. Epub 2023 Jun 15.
3
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.循环核酸与胰腺癌患者的预后相关。
Gastroenterology. 2019 Jan;156(1):108-118.e4. doi: 10.1053/j.gastro.2018.09.022. Epub 2018 Sep 19.
4
Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.初始报告：可切除胰腺癌患者的个体化循环肿瘤 DNA 与生存。
Ann Surg Oncol. 2024 Mar;31(3):1444-1446. doi: 10.1245/s10434-023-14751-2. Epub 2024 Jan 3.
5
Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.循环肿瘤 DNA 作为结直肠癌根治性切除术患者（接受或不接受辅助化疗）微小残留病评估和复发风险的标志物：一项系统评价和荟萃分析。
Int J Mol Sci. 2023 Jun 16;24(12):10230. doi: 10.3390/ijms241210230.
6
Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer.利用循环肿瘤DNA与肿瘤标志物联合评估局部进展期胃癌患者新辅助治疗反应及预测复发情况
Ann Surg Oncol. 2025 Jun 3. doi: 10.1245/s10434-025-17397-4.
7
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.可切除胰腺癌的围手术期改良 FOLFIRINOX：一项非随机对照试验。
JAMA Oncol. 2024 Aug 1;10(8):1027-1035. doi: 10.1001/jamaoncol.2024.1575.
8
Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.切除的胰腺导管腺癌术前和术后KRAS突变循环肿瘤DNA（ctDNA）的预后效用：一项系统评价和荟萃分析
Surg Oncol. 2023 Dec;51:102007. doi: 10.1016/j.suronc.2023.102007. Epub 2023 Oct 10.
9
Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer.基于基因组和表观基因组方法对早期乳腺癌循环肿瘤DNA进行识别的综合肿瘤非特异性评估。
ESMO Open. 2025 Jun;10(6):105286. doi: 10.1016/j.esmoop.2025.105286. Epub 2025 Jun 4.
10
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.高危早期 HER2 阴性乳腺癌患者接受新辅助化疗时循环肿瘤 DNA 的临床意义和生物学特性。
Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4.

本文引用的文献

1
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).新辅助FOLF(IRIN)OX化疗用于可切除胰腺腺癌：一项多中心随机非对照II期试验（PANACHE01 FRENCH08 PRODIGE48研究）
J Clin Oncol. 2025 Jun 10;43(17):1984-1996. doi: 10.1200/JCO-24-01378. Epub 2025 Apr 4.
2
A Review of Circulating Tumor DNA (ctDNA) in Pancreatic Cancer: Ready for the Clinic?胰腺癌循环肿瘤DNA（ctDNA）综述：准备好应用于临床了吗？
J Gastrointest Cancer. 2025 Jan 21;56(1):50. doi: 10.1007/s12029-024-01151-2.
3
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
胰腺导管腺癌新辅助治疗的最佳实践
JAMA Surg. 2025 Feb 1;160(2):172-180. doi: 10.1001/jamasurg.2024.5191.
4
Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis.局部胰腺癌的化疗转换：系统评价和荟萃分析。
Br J Surg. 2024 Oct 1;111(10). doi: 10.1093/bjs/znae244.
5
Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials.新辅助治疗与可切除胰腺癌的直接手术治疗：随机临床试验的重建患者水平荟萃分析。
BJS Open. 2024 Sep 3;8(5). doi: 10.1093/bjsopen/zrae087.
6
New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial.新的生物标志物定义胰腺导管腺癌的生物学边界情况：PANACHE01-PRODIGE48 试验辅助研究结果。
Ann Surg. 2024 Nov 1;280(5):734-744. doi: 10.1097/SLA.0000000000006468. Epub 2024 Aug 5.
7
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.可切除胰腺癌的围手术期改良 FOLFIRINOX：一项非随机对照试验。
JAMA Oncol. 2024 Aug 1;10(8):1027-1035. doi: 10.1001/jamaoncol.2024.1575.
8
Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer.确定胰腺癌可切除性的解剖学和生物学考量
Cancers (Basel). 2024 Jan 23;16(3):489. doi: 10.3390/cancers16030489.
9
Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.在局部胰腺癌新辅助化疗期间，使用下一代测序技术对循环肿瘤DNA作为生物标志物进行前瞻性评估。
Ann Surg. 2025 Jun 1;281(6):997-1005. doi: 10.1097/SLA.0000000000006209. Epub 2024 Jan 23.
10
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.新辅助FOLFIRINOX方案与直接手术治疗可切除胰头癌的比较（NORPACT-1）：一项多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.